<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04587050</url>
  </required_header>
  <id_info>
    <org_study_id>19SM5242</org_study_id>
    <nct_id>NCT04587050</nct_id>
  </id_info>
  <brief_title>Screening for HPV and Cervical Cancer in Young Women With Perinatally Acquired HIV</brief_title>
  <acronym>SHiP</acronym>
  <official_title>Screening for Human Papillomavirus and Cervical Cancer in Young Women With Perinatally Acquired HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Public Health England</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a cross-sectional, observational study of high-risk HPV status, cervical cytology and&#xD;
      HPV vaccine uptake and response in young women with perinatally acquired HIV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational study of cervical cytology assessment, high risk human papilloma&#xD;
      virus (hr-HPV) status, and HPV antibody titres amongst adult women living with perinatally&#xD;
      acquired HIV infection (PaHIV). Eligible consenting participants will have two samples taken;&#xD;
      firstly, a cervical sample tested for cytology and Hr-HPV with the Cepheid GeneXpert HPV;&#xD;
      secondly serum will be assessed for hr-HPV serology. All women with PaHIV, vaccinated and&#xD;
      unvaccinated for HPV, over the age of 18 years will be eligible and will be recruited into&#xD;
      one of two cohorts: (1) sexually active women: full study, cervical and blood sampling (n=50)&#xD;
      or (2) non-sexually active women, blood sampling only (n=30). Follow up for abnormal smear&#xD;
      results or hr-HPV positivity will be arranged through colposcopy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of abnormal cervical cytology</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of high risk HPV by subtype</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of CIN2+</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV type-specific antibody titres (16/18)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>HIV Infections</condition>
  <condition>Human Papillomavirus Infection</condition>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Women with perinatally acquired HIV aged 18 or over who are sexually active</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>Women with perinatally acquired HIV aged 18 or over who are not sexually active</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Human papillomavirus testing</intervention_name>
    <description>HPV test from cervical sample using Cepheid GeneXpert HPV</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cervical cytology</intervention_name>
    <description>Cervical cytology</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>HPV serology</intervention_name>
    <description>HPV type specific serology (16/18) using ELISA from serum samples</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women living with perinatally acquired HIV aged 18 years or older&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria - Cohort 1:&#xD;
&#xD;
          -  Perinatally acquired HIV aged 18+&#xD;
&#xD;
          -  Sexually active&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
        Inclusion Criteria - Cohort 2:&#xD;
&#xD;
          -  Perinatally acquired HIV aged 18+&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
        Exclusion Criteria - Cohort 1:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Not sexually active&#xD;
&#xD;
          -  Previous total abdominal hysterectomy&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
&#xD;
        Exclusion Criteria - Cohort 2:&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tamara Elliott</last_name>
    <role>Study Chair</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tamara Elliott</last_name>
    <phone>02075943931</phone>
    <email>tamara.elliott04@imperial.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Fidler</last_name>
    <email>s.fidler@imperial.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Elliott</last_name>
      <email>tamara.elliott@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 7, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervical screening</keyword>
  <keyword>HPV vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

